MS drug DOES NOT improve the condition of hospitalized COVID-19 patients and is linked to WORSE outcomes
Whats New,
MS drug does NOT improve hospitalized COVID-19 patients and is linked to WORSE outcomes, NIH clinical study…
MS drug does NOT improve hospitalized COVID-19 patients and is linked to WORSE outcomes, NIH clinical study…
Remdesivir will be combined with a multiple sclerosis drug in the next phase of federal testing in hopes that the combination…
Around the world, different countries are taking different approaches to dealing with the global pandemic. Here in Aotearoa…
An updated list of potential treatments for Covid-19.
Obecnie toczy się wiele badań klinicznych, mających wskazać efektywne leczenie COVID-19. W Hongkongu przeprowadzono badanie…
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for May 2020. This roundup…
Here are what the editors at HealthDay consider to be the most important developments in Emergency Medicine for May 2020. This…
Welcome to emDocs cast with Brit Long, MD (@long_brit) and Manpreet Singh, MD (@MprizzleER)! The goal of this podcast is for us…
By Lambert Strether of Corrente. #COVID19 At reader request, I’ve added this daily chart. The data is the John Hopkins CSSE data.
A phase 2 trial has shown that a 2-week course of triple antiviral therapy with (1) interferon beta-1b (used to treat the…
Daniel Griffin provides a clinical update on COVID-19, then we review results showing requirement for the furin site in the SARS…
Alex Nowbar reviews the latest research from the top medical journals. Annals of Internal…
Cancelled operations, at risk groups, and the therapeutic effect of Angela Merkel
A combination of 3 different drugs could be an effective therapy for treating COVID-19 patients. → Support PsyBlog for just $5…
This study suggests that a cocktail of antivirals containing beta interferon may havesome value in controling COVID-19. In this…